The aim of this study was to assess the influence of enrolling site location and enrollment performance on the generalizability of STICH (Surgical Treatment for Ischemic Heart Failure) trial results.
The National Institutes of Health-funded international STICH (Surgical Treatment for Ischemic Heart Failure) trial addresses 2 hypotheses to assess the value of cardiac surgery in patients with ischemic cardiomyopathy (1) . The recently reported outcome of the surgical ventricular reconstruction (SVR) hypothesis confirmed that adding SVR to coronary artery bypass grafting (CABG) in patients with anterior left ventricular (LV) dysfunction decreased LV volume more than CABG alone but did not reduce death or cardiac hospitalization (2) . Cardiovascular specialists have See page 508 raised questions about whether the spectrum of severity of disease at the time of randomization was sufficiently broad to include all patients who might receive survival benefit from SVR (3) . Data from patients now being followed in the surgical revascularization hypothesis will definitively answer whether or not CABG added to evidence-based medical therapy (MED) increases the survival of patients with ischemic cardiomyopathy. This answer will clarify whether an ischemia diagnosis and interventional treatment should be pursued in patients presenting with heart failure symptoms or asymptomatic systolic dysfunction. The importance of STICH trial findings to guide appropriate care decisions for future patients demands an answer to the question: how generalizable are STICH trial results to the patients I see?
The STICH protocol enrollment criteria ensured patient safety and excluded patients without ischemic cardiomyopathy as the most likely cause of death during follow-up. Thereafter, responsible physicians selected 1 of 3 randomization strata, each of which included possible randomization to a cardiac surgical option with significant short-term risk. Patient enrollment was difficult. Variation in equipoise among clinicians and clinical site diversity of structure and care processes produced a broad range of randomization rates. Incremental geographic expansion over 3 years caused enrollment duration to vary among sites. Clinical site location has been shown to influence characteristics of enrolled populations (4) . That STICH was among the top 10 of 129 ongoing clinical trials (7.9%) during 2005 randomizing patients in 20 or more countries (5) emphasizes the need to assess whether enrolling site diversity helped or hindered the generalization of STICH conclusions. The diversity of STICH sites could have aggregated multiple subgroups into discontinuous patient groupings with dissimilar risk. Alternatively, random individual patient diversity both within and among sites could produce a population with a smooth gradation of risk severity. A patient-based metric of baseline risk is needed to document the influence of enrollment decisions made by many physicians in different clinical care environments.
This report describes the STICH risk at randomization (RAR) index, which reflects baseline clinical risk of each patient in context with the full risk spectrum of all randomized patients. Clinical site enrollment rates and geographic location influence on the total randomized patient cohort risk spectrum are compared using the numbers of randomized patients who share the same RAR index number when grouped by clinical site characteristics. Clinical data tabulated from RAR groups created to show the greatest baseline risk discordance place the variability among enrolling sites in clinical context.
Methods
Clinical site and patient recruitment. In 2002, 23 U.S., 7 Canadian, and 2 European clinical sites selected for expertise in clinical research and outstanding care of patients with ischemic cardiomyopathy were activated. Persistently low patient enrollment required incremental expansion that concluded in 2005 with 171 activated clinical sites. Clinical sites were expected to enroll patients into both hypotheses, except for the last sites invited in Argentina, India, and the U.K. These sites were recruited to enroll patients only into the surgical revascularization hypothesis because their help was not needed to attain the 1,000-patient SVR hypothesis recruitment goal. During the 3 years of incremental expansion, 44 activated clinical sites were deactivated by mutual consent because of their inability to enroll any patient.
LV ejection fraction Յ0.35 and coronary artery disease (CAD) amenable to CABG were entry criteria for all STICH patients. Major cardiac disease exclusions were a recent myocardial infarction and need for aortic valve replacement. Any noncardiac disease sufficiently severe to dominate expected 3-year longevity excluded patients. Study design required all STICH patients to receive MED. Patients with Canadian Cardiovascular Society class III or greater ongoing angina on MED and/or Ն50% left main stenosis were not eligible for randomization to MED as their only treatment. Eligibility for SVR required dominant anterior akinesia or dyskinesia amenable to SVR. Patients ineligible for SVR but eligible to receive MED with or without CABG were randomized in stratum A. Patients ineligible for MED alone but eligible to receive CABG with or without SVR were randomized in stratum C. Patients eligible for all 3 treatments were randomized in stratum B. All stratum A and stratum B patients randomized to MED with or without CABG were analyzed in the surgical revascularization hypothesis. All stratum C patients and stratum B patients randomized to CABG with or without SVR were analyzed in the SVR hypothesis.
The clinical judgment of physicians and surgeons responsible for care of STICH-eligible patients determined the enrollment stratum offered for patient consent under the oversight of the ethics committee at each site. The primary ethical concern guiding equipoise for randomization was to offer patients treatment combinations judged to have similar long-term mortalities. Relative benefits of treatment combinations offered within each enrollment stratum might differ among STICH sites. The randomization process stratified treatment assignment by site. Whereas it is not possible to know the underlying enrolling physician judgment used to choose the enrollment stratum, it is possible to map the individual clinical characteristics of enrolled patients to provide evidence of the spectrum of disease severity produced by choices made. Creation of the RAR index. Three Duke Databank for Cardiovascular Diseases CAD prognosis publications (6 -8) Jones et al. August 3, 2010:490-8 The STICH Trial Enrollment inine Ն1.5 mg/dl), heart failure, ejection fraction, Duke CAD index, mitral insufficiency, and cerebrovascular disease ( Table 1) . Individual STICH patient baseline values for these variables entered into the multivariate equation produced a probability of death for each STICH patient that ranged from 0.18387 to 0.99949. The STICH patients were placed in ascending order of their individual prediction of death. All predicted death estimates summed to 1,001.648 corresponded to a 5-year mortality of 0.469, assuming only MED, not surgical treatment, for the 2,136 STICH randomized patients. Using least squares analysis to minimize differences between groups, 32 groups were created to each share one-thirty-second of total predicted deaths as close as was possible with the constraint that the exact risk of each patient had to be assigned to only 1 group. The numbers of patients in groups 1 to 32 deceased as the predicted risk increased, except for groups 31 and 32, which each had 32 patients ( Fig. 1 ). Total predicted deaths per group ranged from a minimum of 30.89 (RAR group n ϭ 31) to a maximum of 31.67 (RAR group n ϭ 28). The average group mortality ranged from 0.228 in group 1 to 0.989 in group 32. By assigning the average group mortality to each 
Figure 1 RAR Development
The continuous green line represents the 2,136 data points of individual patient mortality predicted from the multivariate model. The green boxes represent total predicted deaths for all patients in each risk at randomization (RAR) group. The blue boxes depict the total number of patients in each RAR group. The interrupted orange lines represent the RAR group mortality assigned to each patient in each RAR group. (Fig. 2) . A relatively smooth profile of decline in the number of patients was observed throughout the RAR risk spectrum (Fig. 3) . The median age steadily increased from 48 to 74 years, and the median ejection fraction decreased from 0.30 to 0.20 over the 32 RAR groups. The same RAR group was shared by 890 of the 1,057 patients (84%) from higher enrolling sites and 82% of 1,078 patients from lower enrolling sites (Fig. 4) . The 167 unmatched patients from the higher enrolling sites were predominantly lower-risk patients. The 189 unmatched patients from the lower enrolling sites were predominantly higher-risk patients. There was no consistent relationship between total patient enrollment in each country and the patient-weighted mean RAR index by enrolling country (Fig. 4) . Poland and Russia dominated the enrollment of lower-risk patients, and the U.S. and Canada led countries enrolling higher-risk patients. RAR profiles showed that 807 of 1,064 patients (76%) from countries enrolling lowerrisk patients matched 807 of 1,072 patients (75%) from countries enrolling higher-risk patients (Fig. 5) . However, the RAR profile identified 3 patterns of unmatched patients. In RAR groups 1 to 12, all unmatched patients were from countries enrolling lower-risk patients. RAR groups 13 to 21 showed similar numbers of unmatched patients from both country groupings. In RAR groups 22 to 32, all unmatched patients were from countries enrolling higherrisk patients. Baseline clinical characteristics tabulated for these 3 RAR patient groupings demonstrated statistically significant differences between patients in the lowest and highest RAR groupings, with less difference among patients in RAR groups 13 to 21 (Table 2) . However, the magnitude of statistically significant differences of patients related to country of enrollment appeared sufficiently small to be of little clinical significance in application of STICH results to care decisions for future patients with ischemic cardiomyopathy.
Significant Covariates in the RAR Multivariate Model

Discussion
The Northern New England Cardiovascular Disease Study Group identified patients with poor LV function to have the greatest inconsistency of CABG use compared with guideline recommendations (9) . STICH investigators experienced this divergence of opinion when patients who were STICH eligible by protocol were presented at investigator meetings. Difference in zones of equipoise among physicians responsible for enrolling patients at individual sites combined to produce a smooth risk profile for the entire STICH population. The 4-fold decline in numbers of patients over the 32 RAR groups created with equivalent predicted deaths produced a STICH patient risk profile familiar to clinicians. Ischemic cardiomyopathy as the highest risk subset of all chronic CAD diagnoses includes a rapidly declining number of patients in each RAR group that reflects the highest risk tail of a normal distribution of
The STICH Trial Enrollment all patients with CAD truncated by an ejection fraction Յ0.35 applied as a STICH entry criterion. Enrollment performance varied greatly among sites and was strongly related to baseline clinical risk. The highest enrolling sites tended to enroll more low-risk patients. The lowest-enrolling sites tended to enroll more high-risk patients. The patient risk zone that corresponded to the equipoise zone of the responsible physician appeared to be the strongest determinant of baseline risk of enrolled patients at a site. The profile of the RAR patient distribution suggests that small differences in equipoise windows positioned toward the low-or high-risk direction could produce substantial changes in numbers of patients considered eligible for randomization. Many more low-risk patients than high-risk patients were available if sites were willing to randomize them. However, RAR data confirm that 85% of enrolled patients had similar predicted risk even when clinical sites were grouped by those sites with lowest or highest enrollment performance. Moreover, both site performance groupings enrolled some patients into each RAR group.
Country differences in population demographics also may influence the numbers of low-or high-risk patients presenting with STICH eligibility criteria. The World Health Organization has reported age-standardized mortality rates for cardiovascular disease per 100,000 population to be 324 for Poland and 688 for Russia, the 2 highest enrolling countries of the 7 countries tending to enroll low-risk patients, in contrast to rates of 188 for the U.S. and 141 for Canada, the 2 highest enrolling of the 18 countries tending to enroll more high-risk patients. Country demographics, health care availability, and equipoise differences among physicians most likely contributed in varying degrees to produce observed variation in patient risk among enrolling countries. However, sufficient similarity of patient baseline risk among all enrolling countries has been demonstrated to suggest that STICH enrollment of patients in 26 countries should enhance the generalization of STICH trial results to a broad spectrum of future patients with ischemic cardiomyopathy throughout the world.
The use of a multivariate equation to stratify baseline risks of randomized patients into low-risk, middle-risk, and high-risk groups was first reported by the Veterans Administration Cooperative Study Group in 1981 (10) . Treatment effect was confined to only the high-risk cohort. This early work changed patient selection criteria for CABG from low-to high-risk patients and set the precedent for modeling of baseline 
Figure 2 Schema of Patient Enrollment
This schematic depiction of the STICH (Surgical Treatment for Ischemic Heart Failure) trial design includes numbers of patients randomized to each stratum. Treatment assignments were evidence-based medical therapy (MED) only for 602 patients, coronary artery bypass grafting (CABG) added to MED for 1,033 patients, and CABG and surgical ventricular reconstruction (SVR) added to MED for 501 patients. The 76 stratum B patients assigned to MED plus CABG treatment were used to address both the surgical revascularization hypothesis and the SVR hypothesis. Therefore, 2,136 randomized patients provided 2,212 patients with potential for primary end points for analysis of either or both hypotheses. CAD ϭ coronary artery disease; EF ϭ ejection fraction.
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Patients and Corresponding Clinical Characteristics by RAR
Histogram depicting individual patients at each RAR interval. The corresponding median age, ejection fraction (EF), and Duke coronary artery disease (CAD) index for each risk at randomization (RAR) group and the percent of patients in each RAR group with baseline creatinine (CR) Ͼ1.5 mg/dl, New York Heart Association (NYHA) functional class III to IV heart failure (HF), diabetes, mitral regurgitation 3 to 4ϩ, and vascular disease provided a comprehensive summary of the components of risk for the entire population. A total of 1,614 of 2,136 patients (76%) shared the same risk at randomization (RAR) grouping despite the intentional creation of 2 cohorts to maximize imbalance among countries on the basis of the average baseline risk of patients randomized. RAR groups 1 to 12 included more patients from countries with low patient-weighted mean RAR, and RAR groups 22 to 32 included more patients from countries with high patient-weighted mean RAR. RAR groups 10 to 21 reflected the most even distribution of patients from the 2 country groupings of sites. The baseline characteristics of patients in these 2 groupings are compared in Table 1 . Data are expressed as mean Ϯ SD or as n (%). CAD ϭ coronary artery disease; HF ϭ heart failure; LVEF ϭ left ventricular ejection fraction; NYHA ϭ New York Heart Association; RAR ϭ risk at randomization.
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Comparison of Baseline Clinical Characteristics in 3 RAR
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The STICH Trial Enrollment grouping order of patients was independent of the numeric accuracy of the risk prediction. RAR development included site-reported ejection fraction as the only assessment of LV function. Core laboratory assessments of global and regional LV function reported without knowledge of patient treatment will be used to assess the generalizability of STICH results on the basis of the severity of abnormality represented by the SVR hypothesis patients. Many patient-specific clinical variables that influence decisions for cardiac surgery, such as conduit availability and the suitability of coronary arteries for CABG, were not reported for STICH patients. However, all patients randomized were assessed as eligible for either CABG alone or CABG with SVR by STICH surgeons at each clinical site.
Conclusions
The RAR index methodology provides a clinically useful quantitation of the baseline risk spectrum of patients. Clinical site location introduced greater variation on the profile of baseline clinical risk than enrollment performance. However, 76% of patients shared the same risk profile when grouped by randomization in countries that enrolled more high-or low-risk patients. Differences in the baseline characteristics causing site-related differences in the RAR profile were modest and unlikely to hinder the generalizability of STICH results. Diversity among patients randomized by 127 STICH clinical sites appears more likely to enhance the generalizability of STICH trial results.
